Morning Overview on MSN
Eli Lilly says retatrutide met goals in its first phase 3 diabetes trial
Eli Lilly disclosed that retatrutide, its experimental triple hormone receptor agonist, hit the primary and all key secondary ...
The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak or observation. The first patient was enrolled in a phase 3 trial and was ...
Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results